Original Publication Date: 3 March, 2014
Publication / Source: Future Oncology
Authors: Pasquale Rescigno & Giuseppe di Lorenz
Diagnosis of prostate cancer (PC) at local or regional stages is associated with an excellent prognosis ; however, patients with metastatic PC generally achieve only temporary disease control with hormonal therapy and they eventually develop disease progression despite castrate serum androgen levels. In the last years the number of drugs available for metastatic castration-resistant prostatic cancer (mCRPC), such as abiraterone, cabazitaxel, enzalutamide and sipuleucel-T, has rapidly increased .